SCHEMBL24088778

SCHEMBL24088778

CC(C)(C)OC(=O)NCCc1c[nH]c(-c2ccc(Cl)cc2Cl)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
HPGD P15428 3/20 0.48
HTT P42858 2/20 0.48
KDM4E B2RXH2 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
TP53 P04637 1/20 0.47
GLA P06280 1/20 0.47
MAPT P10636 1/20 0.47
XBP1 P17861 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HSD17B10 Q99714 1/20 0.47
IDO1 P14902 2/20 0.47
STK17B O94768 1/20 0.42
STK17A Q9UEE5 1/20 0.42
LMNA P02545 3/20 0.42
TSHR P16473 2/20 0.41
PKM P14618 1/20 0.41
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31668899 1.00 ALDH1A1 (0.48) ALDH1A1HPGDHTTKDM4ESMN1; SMN2
SCHEMBL24088765 0.84 LMNA (0.47) ALDH1A1HPGDHTTKDM4ESMN1; SMN2
SCHEMBL23778714 0.83 GSK3B (0.45) HPGDCNR1ALPLGSK3B
SCHEMBL24088772 0.82 STK17B (0.42) ALDH1A1HPGDHTTKDM4ESMN1; SMN2
SCHEMBL31668897 0.77 SNCA (0.52) TP53MAPTLMNACNR1CNR2
SCHEMBL23778723 0.77 SNCA (0.52) TP53MAPTLMNACNR1CNR2
SCHEMBL23778655 0.77 SNCA (0.51) CNR1GSK3B
SCHEMBL31668893 0.77 SNCA (0.51) CNR1GSK3B
SCHEMBL23778722 0.77 SNCA (0.45) KMT2AMAPTCNR1CNR2ALPL
SCHEMBL31668891 0.77 SNCA (0.45) KMT2AMAPTCNR1CNR2ALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210380538-A1 NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380538-A1 NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF IDO1, IDO2, NFATC1 ALDH1A1 670/4885HPGD 258/4885HTT 2098/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.